SCHEMBL10025540

SCHEMBL10025540

CN(C)CC1CNc2nc3ccc(OCCCN(C)Cc4ncc[nH]4)cc3n2C1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 1/20 0.33
PDE3A Q14432 1/20 0.33
TLR7 Q9NYK1 4/20 0.33
FGFR1 P11362 4/20 0.32
FGFR2 P21802 3/20 0.32
FGFR4 P22455 3/20 0.32
FGFR3 P22607 3/20 0.32
KDR P35968 3/20 0.32
SMN1; SMN2 Q16637 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
PPARG P37231 1/20 0.31
KDM4E B2RXH2 2/20 0.31
HRH3 Q9Y5N1 1/20 0.31
MAPKAPK2 P49137 1/20 0.31
ACHE P22303 1/20 0.31
MAOB P27338 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31
HRH1 P35367 1/20 0.31
SRC P12931 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6743257 0.88 PPARG (0.32) PDE3BPDE3ATLR7FGFR1PPARG
SCHEMBL10025466 0.87 FGFR1 (0.39) PDE3BPDE3ATLR7FGFR1SMN1; SMN2
SCHEMBL10025535 0.86 KCNA5 (0.35) PDE3BPDE3ATLR7FGFR1PPARG
SCHEMBL10025544 0.85 MAPKAPK2 (0.38) PDE3BPDE3ATLR7PPARGKDM4E
SCHEMBL10025541 0.84 ATM (0.39) PDE3BPDE3ATLR7FGFR1L3MBTL1
SCHEMBL10025539 0.84 PPARG (0.33) PDE3BPDE3ATLR7FGFR1PPARG
SCHEMBL10025542 0.84 MAPKAPK2 (0.36) PDE3BPDE3ATLR7FGFR1PPARG
SCHEMBL10025545 0.84 HTR6 (0.31) PDE3BPDE3ATLR7FGFR1PPARG
SCHEMBL10025543 0.84 TLR7 (0.34) PDE3BPDE3ATLR7MAPKAPK2
SCHEMBL10059137 0.83 ACSS2 (0.39) PDE3BPDE3AKDM4EMAPKAPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207173-B2 Benzimidazoles and analogs thereof as antivirals ISIS PHARMACEUTICALS, INC. (US) 2012-06-26 US disclosed
US-8207173-B2 Benzimidazoles and analogs thereof as antivirals ISIS PHARMACEUTICALS, INC. (US) 2012-06-26 US disclosed
US-20100130513-A1 BENZIMIDAZOLES AND ANALOGS THEREOF AS ANTIVIRALS ISIS PHARMACEUTICALS, INC. (US) 2010-05-27 US disclosed
US-20100130513-A1 BENZIMIDAZOLES AND ANALOGS THEREOF AS ANTIVIRALS ISIS PHARMACEUTICALS, INC. (US) 2010-05-27 US disclosed
US-7642265-B2 Benzimidazoles and analogs thereof as antivirals ISIS PHARMACEUTICALS, INC. (US) 2010-01-05 US disclosed
US-7642265-B2 Benzimidazoles and analogs thereof as antivirals ISIS PHARMACEUTICALS, INC. (US) 2010-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130513-A1 BENZIMIDAZOLES AND ANALOGS THEREOF AS ANTIVIRALS ZC3HAV1, NXF1, ZC3HAV1L PDE3B 2301/4885PDE3A 2534/4885TLR7 3231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.